SAN CARLOS, Calif.--(BUSINESS WIRE)-- Natus Medical Incorporated (Nasdaq:BABY - News) today announced that it was awarded, and has shipped, a $1.3 million order for its ALGO hearing screeners from New South Wales, Australia’s most populous state. The order was received through the Company’s distribution partner working with the local New South Wales government.
“We are very pleased that New South Wales has upgraded to our latest AABR product, reflecting Australia’s commitment to base their newborn hearing screening program exclusively on Natus ALGO products. Our AABR technology is considered to be the gold standard in newborn hearing screening with over 100 published, peer reviewed, clinical studies,” said Jim Hawkins, President and Chief Executive Officer of Natus. “I am also encouraged by the trend of other countries around the world adopting newborn hearing screening programs this year.”
About Natus Medical Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatalogy, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.
ALGO and AABR are registered trademarks of Natus Medical Incorporated.
Additional information about Natus Medical can be found at www.natus.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding Australia’s commitment to base their newborn hearing screening program exclusively on Natus ALGO products. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus’ future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, and risks associated with bringing new products to market, integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.
More information about potential risk factors that could affect the business and financial results of Natus is included in Natus’ annual report on Form 10-K for the year ended December 31, 2009, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.
